Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.
3D is a personalized medicine company, with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease.
Depending on the application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
Earlier this year, Knight entered into both an exclusive license and distribution agreement with 3D for Canada, Israel, Russia and CIS, Sub-Saharan Africa and the Caribbean, and an advisory services agreement. Knight CEO, Jonathan Goodman, also is joining 3D’s advisory board.
In a statement, Mr. Goodman said 3D’s portfolio adds a new dimension to Knight’s product pipeline and “stands to a leave a mark in the fight against cancer.”
Trading in shares of 3D on the TSX Venture Exchange is expected to begin on Sept. 13 under the symbol DXD.
